Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17784577 | 0.85 | CES2 (0.39) | CES2CES1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL17784579 | 0.85 | CES2 (0.39) | CES2CES1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL17795992 | 0.85 | CES2 (0.39) | CES2CES1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL5448715 | 0.79 | CES2 (0.52) | CES2CES1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL9610760 | 0.79 | CES2 (0.52) | CES2CES1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL5448716 | 0.79 | CES2 (0.52) | CES2CES1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL27919056 | 0.77 | ALDH1A1 (0.41) | CES2CES1ALDH1A1MEN1CYP3A4 | |
| SCHEMBL28605331 | 0.75 | CES2 (0.52) | CES2CES1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL17795993 | 0.75 | PDE4A (0.43) | CES2CES1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL855617 | 0.74 | CES2 (0.61) | CES2CES1SMN1; SMN2KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013700-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200129453-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2020-04-30 | — | — | US | disclosed |
| US-10363231-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-07-30 | — | — | US | disclosed |
| US-20170340581-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340581-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2016085939-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129453-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, ADH1B, ADCYAP1R1 | CES2 1178/4885CES1 728/4885SMN1; SMN2 1071/4885 |
| US-20170340581-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, ADH1B, ADCYAP1R1 | CES2 1144/4885CES1 716/4885SMN1; SMN2 1129/4885 |
| US-10363231-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, ADH1B, ADCYAP1R1 | CES2 1144/4885CES1 716/4885SMN1; SMN2 1129/4885 |
| US-11013700-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, ADH1B, ADCYAP1R1 | CES2 1178/4885CES1 728/4885SMN1; SMN2 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.